,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jun 2016', 'fs': 'Jun 2016', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Ogl9Z2AR'}, 'Id': 'a0POZ00000Ogl9Z2AR', 'Event_Date__c': '2016-06-02', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jun 2016', 'Status_History__c': 'a132P000000Ar95QAC'}, 'change': None}]",Jun 2016,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2016', 'fs': 'Sep 2016', 'change': None}, 'Event_Description': {'s': 'Clinical advice required', 'fs': 'Clinical advice required', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Ogl9a2AB'}, 'Id': 'a0POZ00000Ogl9a2AB', 'Event_Date__c': '2016-09-30', 'Event_Description__c': 'Clinical advice required', 'Stage__c': 'Seeking Clinical Advice', 'Formatted_Date__c': 'Sep 2016', 'Status_History__c': 'a132P000000ArCHQA0'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': '<p>The Committee recommended the new formulation and device of adalimumab be listed on the Pharmaceutical Schedule if cost-neutral to the existing presentations of adalimumab, including the future costs of adalimumab with regards to patent extension and the introduction of biosimilar presentations.</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC&#39;s relevant decision-making framework for these recommendations.</p>', 'fs': '<p>The Committee recommended the new formulation and device of adalimumab be listed on the Pharmaceutical Schedule if cost-neutral to the existing presentations of adalimumab, including the future costs of adalimumab with regards to patent extension and the introduction of biosimilar presentations.</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC&#39;s relevant decision-making framework for these recommendations.</p>', 'change': None}, 'Published_Discussion': {'s': '<p>The Committee noted that adalimumab 10 mg, 20 mg and 40 mg subcutaneous presentations are currently listed on Pharmaceutical Schedule, subject to a Special Authority for a range of conditions. The Committee noted that some patients experience significant pain associated with the subcutaneous injection of adalimumab with the currently listed product, however these patients are receiving treatment for chronic conditions that are associated with ongoing pain and the benefit of treatment would usually outweigh the short-term injection related pain.</p><p><br></p><p>Members noted that adalimumab appears to be a more painful injection than etanercept, however only a small number of patients report that injection associated pain was the reason they switched to another injectable biologic (Navarro-Millán et al. PLoS ONE 2016;11(3):e0149781).</p><p><br></p><p>The Committee noted that the new presentation incorporates a two-fold change to the presentation of adalimumab (Humira) to create a citrate-free (CF) formulation, in order to reduce the injection volume, and changes the auto-injector pen device and needle size to aid administration. The current formulation and device could remain available until 30 June 2019 (the end of AbbVie’s current subsidy and delisting protection), although it would be the supplier’s preference to replace the current product sooner. Members noted there may be a potential stock risk in the future if New Zealand continues to list a product that is different to other countries and that PHARMAC staff would need to assess this risk.</p><p><br></p><p>The Committee noted the supplier submitted a new medicine application to Medsafe for the new 40 mg/0.4 ml formulation in March 2016 and registration is expected by May 2017. Members noted that registration of the 10 mg and 20 mg products is not expected until the end of 2018 and these strengths would continue to be available as pre-filled syringes only.</p><p><br></p><p>The Committee noted weak evidence that citrate buffers may be associated with increased pain on subcutaneous injection in comparison with alternatives such as histidine buffer or normal saline (Larsen et al. Basic &amp; Clinical Pharmacology &amp; Toxicology 2006; 98:218–21).\xa0</p><p><br></p><p>Members noted increased injection volume is also associated with increased pain. However, Members considered both concentrations of adalimumab are in a relatively small volume (0.4 ml and 0.8ml). A study by Heise et al. (Diabetes, Obesity and Metabolism 2014;16:971–6) suggested that there may be little difference in pain on injection of either 0.4 or 0.8 ml volume. The Committee considered that it is unclear if a change in needle gauge from 29 to 27 would significantly affect pain on injection.</p><p><br></p><p>The Committee noted four studies provided in the application regarding pain on injection (M10-867, M11-964, M12-783, and M12-159). Two studies were relatively large Phase I trials (M10-867, M12-159) where pre-filled syringes were used to administer a single dose of one of the formulations to healthy subjects. Members noted the Visual Analogue Scale (VAS) scores immediately after injection were statistically significantly higher in the users of the original formulation. However, there was significant variation between subjects as indicated by a very large standard deviation in the numeric results. Pain had diminished significantly by 15 minutes in both treatment arms. Results for both Phase I studies were similar. </p><p><br></p><p>Members noted that two Phase II trials (M11-964 and M12-783) evaluated injection pain following use of a pre-filled syringe of either the current or high-concentration formulation, in treatment naïve and pain experienced patients who had received at least 6 consecutive adalimumab doses prior to screening. Members noted that a recently published paper (Nash et al. Rheumatol Ther August 2016, published online DOI 10.1007/s40744-016-0041-3) provides more detail regarding the VAS scores and shows a statistical difference in VAS immediately after injection between the two formulations. Of note, there is a large numerical difference in scores between the two studies. However, the authors have no explanation for this. Members noted that 67% of patients in the pooled population experienced greater than or equal to 1.3cm less pain following receipt of the 40mg/0.4ml versus the 40mg/0.8ml formulation (p&lt;0.001) and the mean difference in immediate pain after injection for the pooled population was -2.48 (95% CI -2.97 to -2.00; p&lt;0.001). Members noted the minimum clinically important difference in VAS pain score for acute pain is reported to be around 1.3cm (Kelly AM. Emerg Meg J 2001;18:205-7).</p><p><br></p><p>From a clinical efficacy perspective, the Committee considered the formulations appear to be comparable. Members considered from a safety perspective, any potential change in formulation may lead to alterations in protein folding and the potential for a change in antigenicity. Results from the randomised and open label extension trial regarding efficacy and safety suggest that levels of antibody formation are similar between the formulations.</p><p><br></p><p>The Committee noted the sample pen devices provided to members to assess raised no concerns regarding the redesigned pen device. The Committee considered that there may be some advantages in reduced pain and ease of use with the new formulation and device, particularly for those patients that have underlying chronic pain that may contribute to pain experienced with the injection. However, Members noted the broader significance in terms of impact on quality of life and adherence has not been explored.</p><p><br></p><p>The Committee considered there would be no issues with having both formulations on the market at the same time as all presentations are for single dose use and there would be minimal opportunity to mix these up. Members noted some additional training requirements may be necessary to support patients.</p><p><br></p><p>The Committee considered that overall there may be some small benefits from the new formulation and device for some patients, however this should not be a cost to the Pharmaceutical Budget. Members considered the impacts in terms of future costs related to patent extension and impact on the introduction of adalimumab biosimilars to the New Zealand market should be considered in any funding decision to list the new formulation of adalimumab.</p>', 'fs': '<p>The Committee noted that adalimumab 10 mg, 20 mg and 40 mg subcutaneous presentations are currently listed on Pharmaceutical Schedule, subject to a Special Authority for a range of conditions. The Committee noted that some patients experience significant pain associated with the subcutaneous injection of adalimumab with the currently listed product, however these patients are receiving treatment for chronic conditions that are associated with ongoing pain and the benefit of treatment would usually outweigh the short-term injection related pain.</p><p><br></p><p>Members noted that adalimumab appears to be a more painful injection than etanercept, however only a small number of patients report that injection associated pain was the reason they switched to another injectable biologic (Navarro-Millán et al. PLoS ONE 2016;11(3):e0149781).</p><p><br></p><p>The Committee noted that the new presentation incorporates a two-fold change to the presentation of adalimumab (Humira) to create a citrate-free (CF) formulation, in order to reduce the injection volume, and changes the auto-injector pen device and needle size to aid administration. The current formulation and device could remain available until 30 June 2019 (the end of AbbVie’s current subsidy and delisting protection), although it would be the supplier’s preference to replace the current product sooner. Members noted there may be a potential stock risk in the future if New Zealand continues to list a product that is different to other countries and that PHARMAC staff would need to assess this risk.</p><p><br></p><p>The Committee noted the supplier submitted a new medicine application to Medsafe for the new 40 mg/0.4 ml formulation in March 2016 and registration is expected by May 2017. Members noted that registration of the 10 mg and 20 mg products is not expected until the end of 2018 and these strengths would continue to be available as pre-filled syringes only.</p><p><br></p><p>The Committee noted weak evidence that citrate buffers may be associated with increased pain on subcutaneous injection in comparison with alternatives such as histidine buffer or normal saline (Larsen et al. Basic &amp; Clinical Pharmacology &amp; Toxicology 2006; 98:218–21).\xa0</p><p><br></p><p>Members noted increased injection volume is also associated with increased pain. However, Members considered both concentrations of adalimumab are in a relatively small volume (0.4 ml and 0.8ml). A study by Heise et al. (Diabetes, Obesity and Metabolism 2014;16:971–6) suggested that there may be little difference in pain on injection of either 0.4 or 0.8 ml volume. The Committee considered that it is unclear if a change in needle gauge from 29 to 27 would significantly affect pain on injection.</p><p><br></p><p>The Committee noted four studies provided in the application regarding pain on injection (M10-867, M11-964, M12-783, and M12-159). Two studies were relatively large Phase I trials (M10-867, M12-159) where pre-filled syringes were used to administer a single dose of one of the formulations to healthy subjects. Members noted the Visual Analogue Scale (VAS) scores immediately after injection were statistically significantly higher in the users of the original formulation. However, there was significant variation between subjects as indicated by a very large standard deviation in the numeric results. Pain had diminished significantly by 15 minutes in both treatment arms. Results for both Phase I studies were similar. </p><p><br></p><p>Members noted that two Phase II trials (M11-964 and M12-783) evaluated injection pain following use of a pre-filled syringe of either the current or high-concentration formulation, in treatment naïve and pain experienced patients who had received at least 6 consecutive adalimumab doses prior to screening. Members noted that a recently published paper (Nash et al. Rheumatol Ther August 2016, published online DOI 10.1007/s40744-016-0041-3) provides more detail regarding the VAS scores and shows a statistical difference in VAS immediately after injection between the two formulations. Of note, there is a large numerical difference in scores between the two studies. However, the authors have no explanation for this. Members noted that 67% of patients in the pooled population experienced greater than or equal to 1.3cm less pain following receipt of the 40mg/0.4ml versus the 40mg/0.8ml formulation (p&lt;0.001) and the mean difference in immediate pain after injection for the pooled population was -2.48 (95% CI -2.97 to -2.00; p&lt;0.001). Members noted the minimum clinically important difference in VAS pain score for acute pain is reported to be around 1.3cm (Kelly AM. Emerg Meg J 2001;18:205-7).</p><p><br></p><p>From a clinical efficacy perspective, the Committee considered the formulations appear to be comparable. Members considered from a safety perspective, any potential change in formulation may lead to alterations in protein folding and the potential for a change in antigenicity. Results from the randomised and open label extension trial regarding efficacy and safety suggest that levels of antibody formation are similar between the formulations.</p><p><br></p><p>The Committee noted the sample pen devices provided to members to assess raised no concerns regarding the redesigned pen device. The Committee considered that there may be some advantages in reduced pain and ease of use with the new formulation and device, particularly for those patients that have underlying chronic pain that may contribute to pain experienced with the injection. However, Members noted the broader significance in terms of impact on quality of life and adherence has not been explored.</p><p><br></p><p>The Committee considered there would be no issues with having both formulations on the market at the same time as all presentations are for single dose use and there would be minimal opportunity to mix these up. Members noted some additional training requirements may be necessary to support patients.</p><p><br></p><p>The Committee considered that overall there may be some small benefits from the new formulation and device for some patients, however this should not be a cost to the Pharmaceutical Budget. Members considered the impacts in terms of future costs related to patent extension and impact on the introduction of adalimumab biosimilars to the New Zealand market should be considered in any funding decision to list the new formulation of adalimumab.</p>', 'change': None}, 'Published_Application': {'s': '<p>The Committee reviewed an application from AbbVie for the funding of a new formulation of adalimumab citrate-free and new pen device for all indications to replace the existing presentations of Humira 40mg/0.8ml in a pre-filled syringe and auto-injector.\xa0</p>', 'fs': '<p>The Committee reviewed an application from AbbVie for the funding of a new formulation of adalimumab citrate-free and new pen device for all indications to replace the existing presentations of Humira 40mg/0.8ml in a pre-filled syringe and auto-injector.\xa0</p>', 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p>https://pharmac.govt.nz/assets/2016-11-PTAC-minutes.pdf</p>', 'fs': '<p>https://pharmac.govt.nz/assets/2016-11-PTAC-minutes.pdf</p>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2016', 'fs': 'Nov 2016', 'change': None}, 'Event_Description': {'s': None, 'fs': None, 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Ogl9b2AB'}, 'Id': 'a0POZ00000Ogl9b2AB', 'Event_Date__c': '2016-11-03', 'Stage__c': 'Seeking Clinical Advice', 'Links__c': '<p>https://pharmac.govt.nz/assets/2016-11-PTAC-minutes.pdf</p>', 'Formatted_Date__c': 'Nov 2016', 'Published_Recommendation__c': '<p>The Committee recommended the new formulation and device of adalimumab be listed on the Pharmaceutical Schedule if cost-neutral to the existing presentations of adalimumab, including the future costs of adalimumab with regards to patent extension and the introduction of biosimilar presentations.</p><p><br></p><p>The Committee took into account, where applicable, PHARMAC&#39;s relevant decision-making framework for these recommendations.</p>', 'Published_Application__c': '<p>The Committee reviewed an application from AbbVie for the funding of a new formulation of adalimumab citrate-free and new pen device for all indications to replace the existing presentations of Humira 40mg/0.8ml in a pre-filled syringe and auto-injector.\xa0</p>', 'Published_Discussion__c': '<p>The Committee noted that adalimumab 10 mg, 20 mg and 40 mg subcutaneous presentations are currently listed on Pharmaceutical Schedule, subject to a Special Authority for a range of conditions. The Committee noted that some patients experience significant pain associated with the subcutaneous injection of adalimumab with the currently listed product, however these patients are receiving treatment for chronic conditions that are associated with ongoing pain and the benefit of treatment would usually outweigh the short-term injection related pain.</p><p><br></p><p>Members noted that adalimumab appears to be a more painful injection than etanercept, however only a small number of patients report that injection associated pain was the reason they switched to another injectable biologic (Navarro-Millán et al. PLoS ONE 2016;11(3):e0149781).</p><p><br></p><p>The Committee noted that the new presentation incorporates a two-fold change to the presentation of adalimumab (Humira) to create a citrate-free (CF) formulation, in order to reduce the injection volume, and changes the auto-injector pen device and needle size to aid administration. The current formulation and device could remain available until 30 June 2019 (the end of AbbVie’s current subsidy and delisting protection), although it would be the supplier’s preference to replace the current product sooner. Members noted there may be a potential stock risk in the future if New Zealand continues to list a product that is different to other countries and that PHARMAC staff would need to assess this risk.</p><p><br></p><p>The Committee noted the supplier submitted a new medicine application to Medsafe for the new 40 mg/0.4 ml formulation in March 2016 and registration is expected by May 2017. Members noted that registration of the 10 mg and 20 mg products is not expected until the end of 2018 and these strengths would continue to be available as pre-filled syringes only.</p><p><br></p><p>The Committee noted weak evidence that citrate buffers may be associated with increased pain on subcutaneous injection in comparison with alternatives such as histidine buffer or normal saline (Larsen et al. Basic &amp; Clinical Pharmacology &amp; Toxicology 2006; 98:218–21).\xa0</p><p><br></p><p>Members noted increased injection volume is also associated with increased pain. However, Members considered both concentrations of adalimumab are in a relatively small volume (0.4 ml and 0.8ml). A study by Heise et al. (Diabetes, Obesity and Metabolism 2014;16:971–6) suggested that there may be little difference in pain on injection of either 0.4 or 0.8 ml volume. The Committee considered that it is unclear if a change in needle gauge from 29 to 27 would significantly affect pain on injection.</p><p><br></p><p>The Committee noted four studies provided in the application regarding pain on injection (M10-867, M11-964, M12-783, and M12-159). Two studies were relatively large Phase I trials (M10-867, M12-159) where pre-filled syringes were used to administer a single dose of one of the formulations to healthy subjects. Members noted the Visual Analogue Scale (VAS) scores immediately after injection were statistically significantly higher in the users of the original formulation. However, there was significant variation between subjects as indicated by a very large standard deviation in the numeric results. Pain had diminished significantly by 15 minutes in both treatment arms. Results for both Phase I studies were similar. </p><p><br></p><p>Members noted that two Phase II trials (M11-964 and M12-783) evaluated injection pain following use of a pre-filled syringe of either the current or high-concentration formulation, in treatment naïve and pain experienced patients who had received at least 6 consecutive adalimumab doses prior to screening. Members noted that a recently published paper (Nash et al. Rheumatol Ther August 2016, published online DOI 10.1007/s40744-016-0041-3) provides more detail regarding the VAS scores and shows a statistical difference in VAS immediately after injection between the two formulations. Of note, there is a large numerical difference in scores between the two studies. However, the authors have no explanation for this. Members noted that 67% of patients in the pooled population experienced greater than or equal to 1.3cm less pain following receipt of the 40mg/0.4ml versus the 40mg/0.8ml formulation (p&lt;0.001) and the mean difference in immediate pain after injection for the pooled population was -2.48 (95% CI -2.97 to -2.00; p&lt;0.001). Members noted the minimum clinically important difference in VAS pain score for acute pain is reported to be around 1.3cm (Kelly AM. Emerg Meg J 2001;18:205-7).</p><p><br></p><p>From a clinical efficacy perspective, the Committee considered the formulations appear to be comparable. Members considered from a safety perspective, any potential change in formulation may lead to alterations in protein folding and the potential for a change in antigenicity. Results from the randomised and open label extension trial regarding efficacy and safety suggest that levels of antibody formation are similar between the formulations.</p><p><br></p><p>The Committee noted the sample pen devices provided to members to assess raised no concerns regarding the redesigned pen device. The Committee considered that there may be some advantages in reduced pain and ease of use with the new formulation and device, particularly for those patients that have underlying chronic pain that may contribute to pain experienced with the injection. However, Members noted the broader significance in terms of impact on quality of life and adherence has not been explored.</p><p><br></p><p>The Committee considered there would be no issues with having both formulations on the market at the same time as all presentations are for single dose use and there would be minimal opportunity to mix these up. Members noted some additional training requirements may be necessary to support patients.</p><p><br></p><p>The Committee considered that overall there may be some small benefits from the new formulation and device for some patients, however this should not be a cost to the Pharmaceutical Budget. Members considered the impacts in terms of future costs related to patent extension and impact on the introduction of adalimumab biosimilars to the New Zealand market should be considered in any funding decision to list the new formulation of adalimumab.</p>', 'Status_History__c': 'a132P000000ArCwQAK'}, 'change': None}]",Sep 2016,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Apr 2021', 'fs': 'Apr 2021', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Ogl9c2AB'}, 'Id': 'a0POZ00000Ogl9c2AB', 'Event_Date__c': '2021-04-13', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Apr 2021', 'Status_History__c': 'a132P000000Cl82QAC'}, 'change': None}]",Apr 2021,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Mar 2023', 'fs': 'Mar 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Ogl9d2AB'}, 'Id': 'a0POZ00000Ogl9d2AB', 'Event_Date__c': '2023-03-09', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Mar 2023', 'Status_History__c': 'a132P000000EDTFQA4'}, 'change': None}]",Mar 2023,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,,,False,False
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,,,False,False
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'The funding application has been approved.', 'fs': 'The funding application has been approved.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ00000Ogl9e2AB'}, 'Id': 'a0POZ00000Ogl9e2AB', 'Event_Date__c': '2023-07-01', 'Event_Description__c': 'The funding application has been approved.', 'Stage__c': 'Decision', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a13OZ00000Qsc2vYAB'}, 'change': None}]",Jul 2023,False,True
